These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 15030117

  • 21. Novel biologic mechanisms of levosimendan and its effect on the failing heart.
    Parissis JT, Andreadou I, Bistola V, Paraskevaidis I, Filippatos G, Kremastinos DT.
    Expert Opin Investig Drugs; 2008 Aug; 17(8):1143-50. PubMed ID: 18616411
    [Abstract] [Full Text] [Related]

  • 22. [The novelty in the treatment of heart failure].
    Reingardiene D.
    Medicina (Kaunas); 2005 Aug; 41(7):625-31. PubMed ID: 16062032
    [Abstract] [Full Text] [Related]

  • 23. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL, Fitzpatrick JT.
    Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
    [Abstract] [Full Text] [Related]

  • 24. Use of levosimendan, a new inodilator, for postoperative myocardial stunning in a premature neonate.
    Lechner E, Moosbauer W, Pinter M, Mair R, Tulzer G.
    Pediatr Crit Care Med; 2007 Jan; 8(1):61-3. PubMed ID: 17149153
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
    Cleland JG, Takala A, Apajasalo M, Zethraeus N, Kobelt G.
    Eur J Heart Fail; 2003 Jan; 5(1):101-8. PubMed ID: 12559222
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Ca2+ sensitizer superior to catecholamine during myocardial stunning?
    Meyer K, Klocke RC, Schipke JD, Gams E, Korbmacher B.
    Eur J Cardiothorac Surg; 2008 Aug; 34(2):326-31. PubMed ID: 18539040
    [Abstract] [Full Text] [Related]

  • 33. A promising new inotrope: levosimendan.
    Fotbolcu H, Duman D.
    Anadolu Kardiyol Derg; 2010 Apr; 10(2):176-82. PubMed ID: 20382619
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Management of acute cardiac failure by intracoronary administration of levosimendan.
    Caimmi PP, Kapetanakis EI, Beggino C, Molinari C, Giustini G, Crosio E, Reposo G, Micalizzi E, Vacca G, Grossini E.
    J Cardiovasc Pharmacol; 2011 Sep; 58(3):246-53. PubMed ID: 21654504
    [Abstract] [Full Text] [Related]

  • 40. Levosimendan use in several scenarios of acute heart failure.
    Tavares M, Andrade AC, Mebazaa A.
    Arq Bras Cardiol; 2008 Mar; 90(3):211-5. PubMed ID: 18392402
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.